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The article: “Baloon atrial septostomy in pul- 
monary arterial hypertension: A beneficial effect 
on the control of rhythm abnormalities” published 
in the Cardiology Journal (2016, Vol. 23, No. 5, 
539–540) [1] which presents an important problem of 
patients with end-stage pulmonary arterial hyper-
tension (PAH). The chronically elevated pressure 
in pulmonary circulation causes right ventricular 
failure with all its consequences. In the presented 
case, a 31-year-old patient was treated with trepro-
stinil and sildenafil. Due to the supraventricular 
arrhythmia, two procedures of radiofrequency abla-
tion was performed. As a consequence of clinical 
deterioration, the balloon atrial septostomy (BAS) 
was performed which improved the hemodynamic 
status and unexpectedly restored sinus rhythm.
The first report of blade BAS in patients with 
severe primary PAH was presented during the 
World Congress of Pediatric Cardiology in 1993. 
Authors reported a series of 15 children and adult 
patients with severe PAH in which BAS was per-
formed. Interestingly, in 13 patients who survived 
BAS procedure, the long-term survival was essen-
tially improved. In line with other reports, there 
was a significant increase in cardiac index, resulting 
in an increase in systemic oxygen transport [2–4]. 
Unfortunately, a subsequent size reduction or spon-
taneous closure of the defect has been observed 
in many reports requiring repeat BAS procedures 
[5, 6]. To avoid this problem, Micheletti et al. [7] 
implanted a custom-made fenestrated atrial sep-
tal device at the conclusion of BAS procedure to 
maintain the atrial septum opened. In 7 out of 20 
children, the short-term spontaneous closure of 
the created defect was successfully avoided. This 
approach has been implemented by other investi-
gators [8, 9]. A fenestration was performed across 
the wire mesh and the waist of the device and 
the polyester fibers were subsequently removed. 
Platinum markers were placed on the right atrial 
disc of the device to reach the fenestration and to 
perform further procedures in the future. Also, 
the technique of implantation of the modified stent 
(“butterfly stent”) in created interatrial fenestra-
tion was reported [10]. 
The first factory-made fenestrated devices 
were offered by the Occlutech company. The atrial 
flow regulator (AFR) is self-expandable a double- 
-disc nitinol wire mesh construction dedicated to 
create a communication and allow blood flow across 
the interatrial septum (Fig. 1). The disc diameter 
ranges from 16 mm to 23 mm, and fenestration 
diameter is from 4 mm to 10 mm. A 1–2 mm con-
necting waist exists between the two discs corre-
sponding to the thickness of the atrial septum. The 
device has a very high flexibility and adaptability 
with unique braiding. It is repositionable and fully 
retrievable. The first-in-human use was performed 
by Vettukattil’s group in January 2015 [11]. After the 
implantation, there was an immediate hemodynamic 
and symptomatic improvement.
Besides its use, in PAH patients the future 
application of the AFR device may be extended to 
other heart failure populations especially those with 
severe diastolic dysfunction of the left ventricular 
and increased left atrial pressure. Implantation of the 
device may permit left heart decompression via the 
fenestration. Further clinical trials are still required.
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Figure 1. Atrial flow regulator-lateral view and technical drawing; A. Right atrial disc with loading hub; B. Technical 
drawing of right atrial disc with loading hub. 
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